Lp(a) is a plasma lipoprotein particle consisting of a plasminogenlike protein [apo(a) 
Plasma Lp(a) levels vary, in humans, from less than 2 mg/dl to greater than 200 mg/dl. Levels above 20 or 30 mg/dl, present in 25% of the population, are thought to be a risk factor for atherosclerosis either independently or interactively with elevated LDL levels.10-15 Bile acid binding resins, used to lower LDL levels, have had no significant effect on Lp(a) levels.13 Niacin and neomycin, either separately or in combination, have shown some ability to reduce Lp(a) levels.'316 Recently, a new class of lipid lowering drugs, HMG CoA reductase inhibitors, was discovered that operate by reducing liver cholesterol synthesis and causing upregulation of liver LDL receptors. This, in turn, increases the uptake of LDL and decreases plasma LDL levels.17"8 Because Lp(a) particles resemble LDL particles, we examined whether this class of drugs affects Lp(a) levels.
Methods

Subjects
This study was performed in two clinical centers, and three groups of individuals were included. Groups 1 and 2 were studied in Graz, Austria, and group 3 was studied at the Rockefeller University in New York. The patients of the Austrian groups were selected primarily for high Lp(a) plasma con-centrations. Group 1 consisted of five male volunteers without evidence of atherosclerotic disease but with a wide range of initial Lp(a) levels. Two of them were hypercholesterolemic. Each volunteer was treated with 40 mg/day of Simvastatin, and lipoprotein and Lp(a) levels were measured for up to 6 weeks. Group 1 subjects retained their lifestyle and dietary habits during the study. Group 2 included five patients (male and female) referred to the Lipid Clinic in Graz for treatment of hypercholesterolemia. These patients were treated with Simvastatin at a dosage of 10-40 mg/day and observed for up to 9 months. Patients of group 2 were advised to consume a low cholesterol diet (<300 mg/day) with a caloric distribution of protein, carbohydrate, and fat of 15%, 55%, and 30%, respectively. The polyunsaturated to saturated fat (P: S) ratio was 1.5. Group 3 consisted of 14 patients (seven male and seven female) referred to the clinic of the Laboratory of Biochemical Genetics and Metabolism at Rockefeller University in New York for treatment of hypercholesterolemia. All of them had a positive family history for premature atherosclerosis, and 10 of them had coronary heart disease. The Rockefeller University patients followed an American Heart Association phase 2 diet. The cholesterol intake was less than 145 mg/1,800 calories with a caloric distribution of protein, carbohydrate, and fat of 15%, 60%, and 25%, respectively. The P:S ratio was 1.5. Adherence to diet was monitored by completion of a diet questionnaire and by interview with a registered dietitian. Baseline lipid, lipoprotein, and Lp(a) levels were measured after 3 weeks on the diet. These patients were treated with Lovastatin and received each dosage (20, 40 , and 80 mg/day) for 4 full weeks; afterward, plasma lipid, lipoprotein, and Lp(a) levels were measured. The high dosage (80 mg/day) was continued for 6 months, whereupon levels were remeasured. Liver function tests, muscle enzymes, renal function tests, hemoglobin levels, white blood cell counts, platelet counts, clotting functions, and electrolyte levels were monitored for the whole period without significant changes in any of the patients. Secondary hypercholesterolemia was ruled out before inclusion in the study.
Sample Handling
Venous blood was drawn from the forearm and transferred to tubes containing sodium EDTA (ethylenediaminetetraacetic acid). Samples were immediately centrifuged at 1,500 rpm for 15 minutes, and 0.5 ml aliquots of plasma were either kept at 40 C for immediate assay or stored at -70°C for further analysis. Storage under these conditions did not affect Lp(a) measurements. LDL (density, 1.025-1.050), Lp(a) (density, 1.063-1.12), and other lipoproteins were separated by density gradient ultracentrifugation as previously described. (Beckman, Brea, California) to float the VLDL. HDL cholesterol was determined after precipitation of the whole plasma with dextran sulfate magnesium. Appropriate corrections were made for dilution factors, and VLDL, LDL, and HDL cholesterol levels were calculated. In all studies, Lp(a) was quantified by Laurell immunoelectrophoresis21 using a polyspecific antibody from rabbit or horse. The antiserum had been adsorbed by the addition of plasminogen and was free of cross reactivity. Special care was taken to measure Lp(a) in the linear range of standard concentrations that were applied on the same plate. One batch of standards was used throughout this study. All Lp(a) measurements were performed in triplicate. The coefficient of variation of the measurement was less than 3%. The same antibody and the same techniques were used in both laboratories.
Lipoproteins were separated by density gradient ultracentrifugation for compositional analysis, gradient polyacrylamide gel electrophoresis, and negative staining electron microscopy by previously described methods. The hydrated density of lipoprotein fractions was estimated by equilibrium banding density gradient ultracentrifugation. In this analysis, plasma was spun in an SW 41 rotor (Beckman) at 40,000 rpm for 24 hours.
Statistical Analysis
Statistical analysis was performed using a paired t test with Bonferroni's correction for multiple comparisons to compare pretreatment and treatment values.
Results
The lipoprotein profiles before treatment for each person are presented in Table 1 , and the effects of treatment on LDL cholesterol and Lp(a) levels are shown in Figure 1 . In the volunteers of group 1, Simvastatin treatment for 6 weeks resulted in a significant decrease of total cholesterol and triglycerides of 31±4% and 27+9%, respectively. VLDL cholesterol was reduced by 26+9%, LDL cholesterol decreased by 47+5%, and HDL cholesterol increased by 17.7+11%. In group 1, treatment increased Lp(a) by 18+16%. A variety of responses In summary, when baseline pretreatment measurements were compared with treatment measurements of 20 mg Simvastatin (groups 1 and 2) or 40 mg Lovastatin (group 3), all subjects showed a decrease in total cholesterol of 43±5% (p<0.001, mean±SEM), LDL cholesterol of 43±5% (p<0.001), total triglycerides of 35±8% (p<0.005), and VLDL cholesterol of 45±9% (p<0.005). HDL cholesterol increased by 7±8% (NS), and Lp(a) increased by 33±12% (p<0.005). The increase in Lp(a) was greater than the generally accepted 5% margin of reproducibility for Lp(a) determination in half of the patients.
The marked change of LDL cholesterol levels after treatment with HMG CoA reductase inhibitors without a significant change or an increase in Lp(a) levels was a surprising finding. This aroused concern that drug treatment might have in some way altered Lp(a) particle composition resulting in altered immunoreactivity. Because this could confound our observations, physical methods were used to verify that the drugs did not alter Lp(a) composition and that treatment had differing effects on the amounts of LDL and Lp(a). Plasma samples from all of group 1 and from patients 6 and 10 of group 2 were obtained before and during treatment. Lp(a) was isolated by density gradient ultracentrifugation and analyzed chemically. As shown in Table 3 , there were no gross changes induced by treatment in the chemical composition of either LDL or Lp(a). In tThe electrophoretic mobility was determined in 3.5% polyacrylamide gels and calculated in relation to albumin.
particular, the cholesterol content and the lipid to protein ratio remain constant for both particles. Plasma samples were also subjected to gradient polyacrylamide gel electrophoresis (2.5-10%), which
showed that the apparent size of the Lp(a) particles did not change on drug therapy (data not shown). Finally, plasma from the 10 group 1 and 2 subjects before, during, and after therapy was subjected to equilibrium banding density gradient ultracentrifugation. An example is shown in Figure 2 . As can be seen, there were striking changes in the intensity of the LDL band without a noticeable change in concentration or in hydrated density of the Lp(a) band. effect on increasing Lp(a) levels was highly variable. The variability was not a function of the degree of LDL cholesterol lowering caused by the drug, and the mechanism whereby this might occur is totally unknown.
The heightened awareness of increased Lp(a) levels as a risk factor for coronary heart disease led us to evaluate the effect of the HMG CoA reductase inhibitors on these levels. The surprising result that this potent LDL-lowering class of drugs may actually increase Lp(a) levels, especially in patients with high initial Lp(a) levels, suggests that individuals with high Lp(a) levels may require treatment not only with LDL-lowering drugs but also with drugs that lower Lp(a). However, because the increase of Lp(a) due to HMG CoA reductase inhibitors therapy was observed only in half of the patients studied, further work is necessary to identify patients likely to increase Lp(a) levels on treatment with this class of lipid-lowering drugs.
